Whether you are a patient, a scientist, a company or a foundation involved in the fight against Type 1 Diabetes, we hope that you can find here all information you need about our programme "DIABIL-2" supported by the European Commission.

This European programme started on October 1st 2012 aims at testing the efficacy of a safe treatment based on ultra low dose Interleukin 2, for preventing or delaying Type 1 Diabetes disease progression in newly diagnosed patients. You will find our contact details for any additional question.  


We recently demonstrated that ultra-low-dose IL-2 stimulates Tregs without stimulating effector T cells. In humans, (i) we showed that low-doseIL-2 is safe, induces Tregs and is associated with clinical improvement in hepatitis C autoimmune vasculitis; and (ii) we defined an ultra-low dose IL-2 that is well tolerated, increases Treg number and functionality in a dose-finding study in T1D. In a diabetic mouse model (NOD mice), IL-2 can prevent and cure diabetes.

With this strong background – a well-defined mechanism of action; a proof of concept in NOD mice; a proof of concept clinical trial with another autoimmune disease; safety and 


activity/efficacy data in T1D - the DIABIL-2 project propose a phase-IIb clinical trial evaluating the efficacy and safety of ultra-low dose IL-2 for preserving ß-cells in patients with newly-diagnosed T1D.

DIABIL-2 is a double-blind, randomised, placebo-controlled, parallel-group, multicentre European phase-IIb clinical trial.


Details of the clinical trial is available on ClinicalTrial.gov website.

This study will inform us if our approach can preserve remaining endogenous insulin secretion in patients with newly-diagnosed T1D.


In addition, the DIABIL-2 project will allow us:

To further investigate response to ultra-low dose of IL-2 by molecular phenotyping using genetics, genomics, transcriptomics and cutting-edge immunological methods for stratification of individualized patient care.

To strengthen basic and clinical European Scientific Excellence by the dissemination of landmark results and the foundation of a European network of excellence operating in the T1D field.





Publication in DIABETES
Aixin Yu et al., Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes, Diabetes June 2015 64:6 2172-2183


DIABIL-2 at the IDS congress  - April 2015

The Immunology of Diabetes Society 14th International Congress tok place in Munich on 12-16 April 2015. DIABIL-2co-sponsored a session on Sunday 12th April: “Targeting a cytokine pathway”. http://www.ids2015.org/conference-programme.html


DIABIL-2 2nd Annual Meeting - 10 & 11 October 2014

DIABIL-2 partners gathered in Paris on 10th - 11th October 2014 for the 2nd Annual Meeting. This was also the occasion to bring together the clinical centres that are participating in the DIABIL-2 European trial to be launched in the coming months.


Publication in The Lancet Diabetes & Endocrinology

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Click here to view more.


DIABIL-2 1st General meeting in Basel on November 12th and 13th 2013
This meeting gathered all DIABIL-2 partners from UK, Germany, Switzerland and France for presenting the progress made since the launch of the project a year ago as well as the next achievements for the forthcoming year. The meeting took place in the presence of the members of the Independent Scientific Advisory Board of the project, who will carefully monitor and advise us in our activities.